Bristol-Myers Squibb Co
XETRA:BRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
XETRA:BRM
|
US |
|
H
|
Hunter Douglas NV
F:HUD
|
NL |
Multiples-Based Value
The Multiples-Based Value of one
BRM
stock under the Base Case scenario is
58.66
EUR.
Compared to the current market price of 51.2 EUR,
Bristol-Myers Squibb Co
is
Undervalued by 13%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
BRM Competitors Multiples
Bristol-Myers Squibb Co Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
XETRA:BRM
|
117.8B EUR | 2.5 | 17 | 7.2 | 8.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.8 | 40.5 | 27.4 | 29.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.2 | 21.7 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.5 | 16 | 9.9 | 12.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
221.8B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.2 | 13.1 | 16.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.5 | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| FR |
|
Sanofi SA
PAR:SAN
|
99.1B EUR | 2.1 | 12.7 | 10.6 | 10.6 |